ID | 67697 |
フルテキストURL | |
著者 |
Nishikori, Asami
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Nishimura, Midori Filiz
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Tomida, Shuta
Center for Comprehensive Genomic Medicine, Okayama University Hospital
Kaken ID
researchmap
Chijimatsu, Ryota
Center for Comprehensive Genomic Medicine, Okayama University Hospital
Ueta, Himawari
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Lai, You Cheng
Department of Medical Biotechnology and Laboratory Science, Chang Gung University
Kawahara, Yuri
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Takeda, Yudai
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Ochi, Sayaka
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Haratake, Tomoka
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Ennishi, Daisuke
Center for Comprehensive Genomic Medicine, Okayama University Hospital
Nakamura, Naoya
Department of Pathology, Tokai University School of Medicine
Momose, Shuji
Department of Pathology, Saitama Medical Center, Saitama Medical University
Sato, Yasuharu
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
ORCID
Kaken ID
researchmap
|
抄録 | Idiopathic multicentric Castleman disease (iMCD) is a type of Castleman disease unrelated to the Kaposi sarcoma-associated herpesvirus/human herpesvirus type 8 (KSHV/HHV8) infection. Presently, iMCD is classified into iMCD-IPL (idiopathic plasmacytic lymphadenopathy), iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), and iMCD-NOS (not otherwise specified). The most common treatment for iMCD is using IL-6 inhibitors; however, some patients resist IL-6 inhibitors, especially for iMCD-TAFRO/NOS. Nevertheless, since serum IL-6 levels are not significantly different between the iMCD-IPL and iMCD-TAFRO/NOS cases, cytokines other than IL-6 may be responsible for the differences in pathogenesis. Herein, we performed a transcriptome analysis of cytokine storm-related genes and examined the differences between iMCD-IPL and iMCD-TAFRO/NOS. The results demonstrated that counts per million of STAT2, IL1R1, IL1RAP, IL33, TAFAIP1, and VEGFA (P < 0.001); STAT3, JAK2, MAPK8, IL17RA, IL18, TAFAIP2, TAFAIP3, PDGFA, VEGFC, CXCL10, CCL4, and CXCL13 (P < 0.01); and STAT1, STAT6, JAK1, MAPK1, MAPK3, MAPK6, MAPK7, MAPK9, MAPK10, MAPK11, MAPK12, MAPK14, NFKB1, NFKBIA, NFKBIB, NFKBIZ, MTOR, IL10RB, IL12RB2, IL18BP, TAFAIP6, TNFAIP8L1, TNFAIP8L3, CSF2RBP1, PDGFB, PDGFC, and CXCL9 (P < 0.05) were significantly increased in iMCD-TAFRO/NOS. Particularly, upregulated IL33 expression was demonstrated for the first time in iMCD-TAFRO/NOS. Thus, inflammatory signaling, such as JAK-STAT and MAPK, may be enhanced in iMCD-TAFRO/NOS and may be a cytokine storm.
|
キーワード | idiopathic multicentric Castleman disease
cytokine storm
transcriptome analysis
|
発行日 | 2024
|
出版物タイトル |
Journal of Clinical and Experimental Hematopathology
|
巻 | 64巻
|
号 | 4号
|
出版者 | Japanese Society for Lymphoreticular Tissue Research
|
開始ページ | 297
|
終了ページ | 306
|
ISSN | 1346-4280
|
NCID | AA11556796
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2024 The Japanese Society for Lymphoreticular Tissue Research
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.3960/jslrt.24061
|
ライセンス | https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ja
|
助成機関名 |
Japan Society for the Promotion of Science
MHLW
Japan Agency for Medical Research and Development
Ryobi Teien Memory Foundation
|
助成番号 | JP 23K1447605
24KK0172
JPMH 23FC1025
JP 22ek0109589h0001
|